Last reviewed · How we verify

Lispro Insulin and glargine insulin

Diabetes Care Center · Phase 1 active Small molecule

Lispro Insulin and glargine insulin is a Small molecule drug developed by Diabetes Care Center. It is currently in Phase 1 development.

At a glance

Generic nameLispro Insulin and glargine insulin
SponsorDiabetes Care Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lispro Insulin and glargine insulin

What is Lispro Insulin and glargine insulin?

Lispro Insulin and glargine insulin is a Small molecule drug developed by Diabetes Care Center.

Who makes Lispro Insulin and glargine insulin?

Lispro Insulin and glargine insulin is developed by Diabetes Care Center (see full Diabetes Care Center pipeline at /company/diabetes-care-center).

What development phase is Lispro Insulin and glargine insulin in?

Lispro Insulin and glargine insulin is in Phase 1.

Related